PIK3CA and neoplasm: Similarly, in the BELLE-2 randomised clinical trial assessing response to buparlisib in previously treated HR+/HER2- locally advanced or metastatic breast cancer patients, longer PFS was detected specifically in patients where PIK3CA mutations were detected in circulating tumour DNA (ctDNA).